O'Melveny Steers Cancer-Focused Biotech Firm's $58M IPO
Cancer-focused biotechnology firm Adlai Nortye Ltd. saw shares plunge in debut trading Friday after pricing a downsized $57.5 million initial public offering, represented by O'Melveny & Myers LLP and underwriters counsel...To view the full article, register now.
Already a subscriber? Click here to view full article